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Abstract 
High level of phospholipase A2 (PLA2) activity is found in serum and biological fluids during 
the acute phase response (APR). Extracellular PLA2 in fluids of patients with inflammatory 
diseases such as sepsis, acute pancreatitis or rheumatoid arthritis is also associated with 
propagation of inflammation. PLA2 activity is involved in the release of both pro- and anti-
inflammatory lipid mediators from phospholipids of cellular membranes or circulating 
lipoproteins. PLA2 may thus generate signals that influence immune responses. Here, group 
III secretory PLA2s were tested for their ability to promote generation of functionally mature 
human dendritic cells (DC). PLA2 treatment of differentiating monocytes in the presence of 
GM-CSF and IL-4 yielded cells with phenotypical and functional characteristics of mature 
DC. This maturation was dependent on the dose of PLA2 and PLA2-generated DC stimulated 
interferon gamma secretion by allogeneic T cells. The effects of PLA2 on DC maturation was 
mainly dependent on enzyme activity and correlated with the activation of NF-κB, AP-1 and 
NFAT. The data suggest that transient increase in PLA2 activity generates signals that 
promote transition of innate to adaptive immunity during the APR. 
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 1 Introduction 
 
The acute phase response (APR) is a non specific physiological response to aggression of the 
organism whose main function is to favor tissue repair and pathogen elimination. This alarm 
system can be triggered by different kinds of stress such as injury, physical trauma or 
infection and result in the release of inflammatory mediators that induce transient and drastic 
modifications of plasma composition [1]. The concentration of numerous plasma proteins 
called acute phase reactants can be increased up to a thousand fold while that of other proteins 
like albumin is drastically decreased [2]. This systemic response of APR has numerous 
consequences especially on lipid metabolism. It is accompanied by alterations in lipoprotein 
composition and result in accumulation of oxidized low density lipoproteins (LDL) and 
generation of modified phospholipids [3, 4]. Because phospholipase A2 (PLA2) activity 
increases following cell injury and during inflammatory conditions, secretory PLA2 can be 
considered as an acute phase reactant [5]. 
PLA2s are enzymes that hydrolyze phospholipids at the sn-2 position to produce 
lysophospholipids and free fatty acids. Mammalian PLA2 isoenzymes are subdivided into four 
families, including cytosolic calcium-dependent and independent PLA2s, secretory PLA2s 
(sPLA2) and PAF-acetylhydrolases [6]. sPLA2s are low molecular weight enzymes that use 
calcium as cofactor. High amounts of sPLA2s are also found in snake and bee venoms. Bee 
venom group III sPLA2 is the major allergen of hymenoptera venom and is largely used in 
desensitization treatments [7]. A human group III sPLA2 (hGIII sPLA2) with high homology 
to the bee venom enzyme has recently been described [8]. High level of sPLA2 has been 
measured in synovial fluid of rheumatoid arthritis patients [9, 10], bronchoalveolar lavage of 
asthmatic patients [11] or in serum of individuals with systemic inflammatory disorders such 
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as septic shock [12], acute pancreatitis [13] and autoimmune diseases [14]. Some sPLA2s 
were characterized as acute phase reactants playing a role in atherosclerosis by altering high 
and low density lipoprotein catabolism and uptake [15].  
The effects of sPLA2s can be associated to their catalytic properties or to the engagement of 
cellular receptors [16, 17]. Different types of membrane receptors for sPLA2s have been 
identified. N-type receptors are mostly expressed in brain and bind neurotoxic sPLA2 with 
high affinity. M-type receptors that belong to the C-type lectin family are expressed in various 
tissues and display low affinity for the bee venom PLA2 (for review see [18]). Binding of 
PLA2 to the mannose receptor and glycosaminoglycans has also been reported and may 
trigger cellular activation and release of bioactive molecules like cytokines, leukotriene B4 
and platelet-activating factor (PAF) [19-21].  
PLA2 hydrolysis of PC can generate bioactive lipids such as lysophosphatidylcholine (LPC) 
and non esterified poly-unsaturated fatty acids that exert various effects on immune cells. We 
have recently shown that LPC promotes mature DC generation from differentiating 
monocytes [22, 23]. Non esterified poly-unsaturated fatty acids can modulate toll-like 
receptor (TLR) signaling, resulting in modified activation of NF-κB [24]. Furthermore, 
eicosanoids which are downstream metabolites of the PLA2 reaction, are involved in the 
regulation of functional properties of dendritic cells (DCs) with diverse effects. For instance, 
lipoxin A4 strongly inhibits IL-12 production by mature DCs [25], and prostaglandin E2 
regulates the migratory capacity of DCs [26] and their secretion of IL-12 [27].  
PLA2-mediated processing of PC can generate a number of bioactive molecules with opposite 
effects on immunity. Since the secretion of PLA2s is strongly stimulated during the acute 
phase response, we asked whether an increased PLA2 activity can generate signals identified 
by the innate immune system that would promote transition to an adaptive response. Here we 
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describe the effect of group III sPLA2s on the generation of functional human DC derived 
from monocytes.  
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2 Results 
 
2.1 Phenotypic maturation induced by group III sPLA2 
 
We have previously shown that LPC can induce the differentiation of mature DC directly 
from monocytes when it is added for the last 24 h of monocyte differentiation in the presence 
of GM-CSF and IL-4 [22, 23]. LPC can be generated from PC by PLA2 hydrolysis. Therefore, 
we asked whether sPLA2 could exert the same effects on differentiating monocytes. As 
expected, monocytes incubated for 6 days with GM-CSF and IL-4 differentiated to immature 
DC (control) expressing high levels of CD1a but no CD14, low levels of HLA-DR and CD40 
but no CD86, CD80 and CD83 (figure 1A). When bee venom sPLA2 was introduced in the 
culture medium for the last 24 h of differentiation, cells obtained at day 6 had the phenotype 
of mature DC with enhanced expression of HLA-DR, CD86, CD80, CD83 and CD40. The 
maturation induced by this PLA2 was weaker than that induced by LPS (figure 1A), especially 
for the up-regulation of CD83 and CD40. The addition of the endotoxin inhibitor polymixin B 
had no effect on PLA2-induced maturation (figure 1A) whereas it strongly inhibited an 
important dose of LPS (10 ng/ml) (data not shown). The maturation was dependent on the 
dose of PLA2 and maximal CD86 induction was obtained with 5 U/ml of PLA2 (figure 1B). 
Further experiments with bee venom PLA2 were therefore realized with 5 U/ml.  
 
2.2 Functional mature DC promoted by group III sPLA2 
 
To analyze their functional properties, PLA2-treated DC were washed and co-cultured with 
allogeneic T cells. We found that these DC were able to stimulate IFNγ secretion (figure 2A) 
whereas no IL-4 nor IL-5 secretion could be detected (data not shown). The concomitant 
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addition of polymixin B with PLA2 during DC differentiation did not affect the functional 
maturation induced by PLA2 (data not shown). To confirm the Th1 polarization of T cells, 
intracellular IL-4 and IFNγ synthesis by T cells was analyzed after restimulation by IL-2. T 
cells co-cultured with immature control DC led to a low number of IFNγ-producing cells and 
no production of IL-4 (figure 2B). Although with less efficiency than cells treated with 1 
µg/ml LPS, PLA2-generated DC increased the percentage of IFNγ-secreting T cells but not 
that of IL-4-producing T cells (figure 2B). Therefore, bee venom PLA2 was able to generate 
mature DC that have the ability to induce a Th1-oriented response in vitro. This polarization 
could not be explained by IL-12 secretion, since PLA2-treated cells did not secrete IL-12p70 
and secreted small amounts of IL-12p40 (43 ± 29 pg/ml) that were only slightly above that of 
untreated cells (13 ± 9 pg/ml).  
 
2.3 The catalytic domain of human group III sPLA2 induces DC maturation 
 
The catalytic domain of the human homologue of group III bee-venom PLA2 (hGIII sPLA2), 
that was produced as a recombinant protein in S2 insect cells and purified to homogeneity 
[28] also induced the maturation of DC, enhancing the expression of presenting and 
costimulatory molecules (figure 3A). These cells were functionally mature since they also 
stimulated the secretion of IFNγ by allogeneic T cells (figure 3B). Because of the rarity of this 
purified human PLA2, the following experiments were performed with the bee venom 
enzyme. 
 
2.4 PLA2 binding and internalization by DCs 
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Bee venom PLA2 was labeled with fluorescent Alexa488 to follow its binding and 
internalization by cells. Differentiating monocytes were harvested at day 5 (before any 
treatment by PLA2) and incubated on ice with increasing doses of fluorescent PLA2. The 
binding of PLA2 on cells was low, especially at the dose of 4 µg/ml, corresponding to the 
optimal active dose of 5 U/ml. Nevertheless, PLA2 binding reached saturation at 8 µg/ml 
(~500 nM) for 106 cells (figure 4A). This binding could be inhibited by competition with non-
labeled PLA2 and 80 % inhibition was observed with a ten-fold excess of non labeled PLA2 
(figure 4B). The data suggest that PLA2 binds to a specific receptor. The high concentration of 
bee venom PLA2 (~500 nM) necessary to reach saturation suggests that this receptor may be 
of low affinity. Chelation of calcium by 2 mM EDTA and addition of 5 µg/ml of mannan 
inhibited the binding of Alexa-PLA2 by 50 % and inhibitions by mannan and EDTA were not 
additive (data not shown), suggesting that at least one C-type lectin is involved in PLA2 
binding to differentiating monocytes. These results may be in line with those of 
Mukhopadhyay and Stahl showing that bee venom PLA2 binds to the macrophage mannose 
receptor (CD206) [29], a C-type lectin that is expressed on immature DCs. 
When the enzyme was incubated with cells at 37°C, the fluorescent PLA2 was efficiently and 
rapidly internalized (figure 4C). Internalized PLA2 could be visualized by a punctuated 
labeling in almost all cells (figure 4D). Binding / Internalization experiments revealed that the 
membrane receptor for PLA2 could trigger internalization of its ligand (figure 4E). Therefore, 
during the 24 h treatment of DC, PLA2 is likely to be internalized by both receptor-mediated 
endocytosis and constitutive pinocytosis which is highly efficient in immature DCs. The 
relative contribution of each pathway remains to be determined. 
 
2.5 Mechanism of action of sPLA2 
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The effect of PLA2 on DCs may be due either to a direct enzymatic effect or to membrane 
signals induced by PLA2 binding to surface receptors. The catalytic activity of the enzyme can 
be inactivated by progressive heating at 95°C, as measured by hydrolysis of arachidonoyl-
thio-PC (figure 5A). After denaturation of PLA2 for various periods of time (0 to 30 min), the 
same amount of enzyme (4 µg/ml) was added to the culture medium at day 5 of monocyte 
differentiation. The maturation state of the cells was estimated 24 hours later by analyzing 
their phenotype. We previously observed that CD86 is the most sensitive and reliable marker 
of activation, therefore CD86 expression was plotted according to the enzyme activity 
measured after heating (figure 5B). The induction of maturation correlated with the 
phospholipase activity, with a drastic decrease in CD86 induction when PLA2 was heated for 
only 5 min. After heat-inactivation of the enzyme for 30 min, its binding to DCs was not 
affected (figure 5C), indicating that sPLA2 binding is not involved or not sufficient by itself to 
induce DC activation. Thus, the generation of mature DC by PLA2 appears to depend on the 
enzyme activity.  
 
2.6 Transcription factors activated by sPLA2 
 
Activation signals of DC can induce maturation through several distinct pathways. Signals 
like those engaging Toll-Like Receptors (TLR) or inflammatory cytokine receptors result in 
the activation of NF-κB. Others like DC maturation triggered by FcR or LPC are independent 
of NF-κB. The role of nuclear factors was studied by electrophoretic mobility shift assays 
(EMSA) using specific DNA probes. As shown in figure 6 (A and C), NF-κB is activated by 
PLA2 treatment. NF-κB binding activity is induced after 4 hours of treatment with PLA2 and 
remains highly activated after 24 hours. PLA2 treatment also induced the activation of AP-1 
and NFAT (figure 6B-C). Peroxisome proliferator-activated receptors gamma (PPARγ) are 
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ligand–dependent transcription factors that are inhibited by LPC and activated by lipids such 
as HODE and HETE derived from linoleic and arachidonic acid [30]. They are involved in the 
regulation of inflammation and lipid metabolism. Using a DNA probe containing a 
peroxisome proliferator response element from CD36 promoter, no significant variation of 
PPARγ could be observed (figure 6B-C).  
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 3 Discussion 
The aim of this work was to determine whether an increase in sPLA2 activity resulted in the 
release of endogenous lipid signals that can be detected by the innate immune system. In this 
paper, it is shown that treatment of differentiating monocytes by the bee venom PLA2 and the 
catalytic domain of hGIII sPLA2 generates cells with phenotypic and functional 
characteristics of mature DCs. PLA2-generated DC could activate a Th1 type response by 
allogeneic T cells, inducing the secretion of IFNγ but not that of IL-4. Although the bee 
venom PLA2 binds to specific membrane receptors on DCs, its biological effects seem to be 
associated to its enzymatic activity. We could exclude PLA2 contamination by endotoxins 
because: i, polymixin B did not affect PLA2-induced phenotypic and functional maturation, ii, 
sPLA2 did not induce important secretion of IL-12 and iii, heating of the enzyme completely 
abolished its effect. PLA2 treatment leading to mature DC generation also activated 
transcriptional factors known to be involved in the activation and regulation of an immune 
response. The data supported and extended the notion recently proposed that lipid mediators, 
whose production is highly controlled during the APR, may play a central role in 
immunoregulation. 
The biological effect of the bee venom PLA2 on DCs appears dependent on its enzymatic 
activity. Although most of the study was performed with bee-venom PLA2, similar data were 
obtained with the highly purified catalytic domain of hGIII sPLA2. Several other PLA2 may 
also participate to DC maturation in vivo. For instance, the lipoprotein-associated plasmatic 
PLA2 also called PAF-acetylhydrolase hydrolyzes oxidized phospholipids with shortened 
fatty acid in sn-2 position, increasing LPC content in oxLDL [31]. The human group IIA, V or 
X sPLA2s produced under inflammatory conditions can also modify lipoproteins and generate 
high amounts of LPC in LDL [32-34]. Lipolytic modifications of LDL by bee venom PLA2 
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increased the affinity of LDL for proteoglycans and glycosaminoglycans [35]. Under our 
experimental conditions, addition of purified LDL in the culture medium did not enhance 
PLA2 effect on DC generation (data not shown). This may be due to the presence of albumin 
which is known to retain and inactivate fatty acids and lysophospholipids generated by PLA2 
hydrolysis of native lipoproteins. Therefore these lipid mediators are likely to be the most 
efficient when generated via PLA2-mediated processing of membrane phospholipids. PLA2 
could also hydrolyze phospholipids from membranes of endocytic compartments following 
internalization of the enzyme. Human group II, V, X and XII as well as human and bee-
venom group III sPLA2 have been reported to generate external lipid mediators and hydrolyze 
phospholipids from the outer membrane leaflet [28, 36]. Lipids generated at the cell 
membrane may be directly detected by membrane receptors or enter the cells to be 
metabolized or directly interact with nuclear receptors.  
The treatment of DCs with the bee venom PLA2 results in NF-κB, AP-1 and NFAT activation. 
These transcription factors control the expression of numerous genes involved in the 
regulation of immunity. The role of NF-κB in DC maturation has been extensively studied 
[37-39]. This nuclear factor regulates genes involved in inflammation such as inflammatory 
cytokines (IL-1β, TNFα, IL-12, etc…) and chemokines (IL-8, MCP, etc…). It is also 
implicated in LPS, CD40 or TLR-induced DC maturation. NFAT has been widely studied in 
T-cell activation where it plays a key role in antigen receptor-mediated responses by 
controlling the expression of a number of genes including cytokines such as IL-2, IL-4, 
TNFα, IFNγ and ligands such as CD40 and Fas ligand (reviewed by [40]). AP-1 proteins are 
regulated by PKC and Ras/Rac dependent pathways. AP-1 and NFAT transcription factors 
can form stable complexes that bind composite NFAT:AP-1 DNA sites. These composite sites 
have been identified in genes involved in the immune response such as IL-2, GM-CSF and 
IFNγ [41]. Activation of these transcription factors may reflect the diversity of bioactive 
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molecules generated under PLA2 treatment and may be an efficient way to integrate complex 
signals, enabling a fine tuning of biological responses. PLA2-induced generation of mature 
DC probably results from the combined effects of several lipid mediators produced directly or 
indirectly by this enzyme. Among the various molecules resulting from PLA2 activity, LPC 
was the best candidate to mediate PLA2 effects on DC. Indeed, using the experimental 
procedures described above, we have shown previously that LPC is the major lipid mediator 
of oxidized LDL that can promote mature DC generation from differentiating monocytes by a 
G-protein coupled membrane receptor dependent pathway [22]. However, the transcription 
factors activated by LPC are different from those activated after bee venom PLA2 treatment 
[30]. Therefore, LPC is unlikely to be directly responsible for the effects of PLA2 on DC 
generation. Activation of NF-κB may be initiated by derivatives of both LPC and arachidonic 
acid. Further work is required to identify the lipid mediators and their signaling pathway. 
Although bee venom sPLA2 is a major allergen in humans, PLA2-generated DC do not display 
a Th2-type function in vitro when cells are obtained from non-allergic donors. Accordingly, it 
is known for other allergens such as Der p 1, one of the major allergens of the house dust 
mite, that Th2 polarization of monocyte-derived DC is due to the allergic status of the donor 
[42]. It would therefore be interesting to compare the effects of PLA2 on monocytes and DC 
from allergic versus non allergic individuals and to know whether environmental factors 
including histamine could reorient the function of PLA2-generated DC toward a Th2-type as 
previously observed for LPS [43]. The overall data presented here suggest that sPLA2 like bee 
venom or hGIII PLA2 can generate lipid mediators with immunoregulatory functions in vitro. 
Increased PLA2 activity during the APR may thus favor the development of the adaptive arm 
of immunity. 
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4 Material and methods 
 
4.1 Differentiation of monocyte-derived dendritic cells 
 
PBMC were isolated from human peripheral blood by density gradient centrifugation on 
Ficoll-Hypaque (Amersham Biosciences, Uppsala, Sweden). Mononuclear cells were 
separated from PBL by centrifugation on a 50 % Percoll solution. Monocytes were purified by 
immunomagnetic depletion (Dynal, Oslo, Norway) using a cocktail of monoclonal Abs anti-
CD19 (4G7 hybridoma), anti-CD3 (OKT3, ATCC, Rockville, MD, USA) and anti-CD56 
(NKH1, Beckman Coulter, Fullerton, CA, USA). Monocytes were more than 90 % pure as 
assessed by CD14 labeling. Monocytes were differentiated to immature DC during 6 days 
with 40 ng/ml human recombinant GM-CSF and 250 U/ml human recombinant IL-4 in RPMI 
1640 (Life Technologies, Rockville, MD, USA) supplemented with 2 mM glutamine (Life 
Technologies), 10 mM Hepes (Life Technologies), 40 ng/ml gentamycin (Life Technologies) 
and 10 % lipoprotein-deficient fetal calf serum (LPDS, Sigma, St Quentin-Fallavier, France). 
At the end of the differentiation (day 6), cells were harvested and analyzed. Cells were CD14- 
CD1a+ and viability was superior to 90 %.  
 
4.2 PLA2 treatment 
Bee venom PLA2 (Sigma; min. purity 87%; 1360 U/mg protein; one unit will hydrolyze 1.0 
µmole of soybean L-α-phosphatidylcholine per min at pH 8.9 and 25°C) was dissolved in 100 
mM Hepes buffer pH 8.5, aliquoted and stored at -20°C. The catalytic domain of the human 
group III sPLA2 was produced in insect cells and purified as previously described [28]. A 50X 
solution of PLA2 was prepared extemporaneously by dilution in 100 mM Hepes / 5 mM 
CaCl2 pH 8.5 buffer and 20 µl was added to 1 ml of differentiating DC at day 5. Cells were 
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incubated for 24 h with the indicated doses of PLA2 or LPS (1 µg/ml). Control cells were 
incubated with 20 µl of buffer alone. At day 6, cells and supernatants were harvested and 
analyzed. When indicated, polymixin B (10 µg/ml; Sigma) was added to the culture 10 min 
before sPLA2 (5 U/ml) or LPS (10 ng/ml) addition.  
 
4.3 PLA2 inactivation 
 
sPLA2 (250 U/ml) in Hepes-CaCl2 buffer was heated at 95°C for 5 to 30 min and the enzyme 
was kept on ice until the assay. Enzyme activity was assayed by arachidonoyl-thio-PC 
hydrolysis (Cayman Chemicals, Ann Arbor, MI, USA) as described [44]. 5 µl of buffer (150 
mM NaCl / 10 mM CaCl2 / 80 mM Hepes / 4 mM Triton X-100 / 30 % glycerol / 1 mg/ml 
BSA pH 7.4) was added to 10 µl of heated PLA2 and incubated for 60 min at room 
temperature with 200 µl of 1.5 mM arachidonoyl-thio-PC in the same buffer. After addition of 
10 µl of DTNB/EGTA solution (25 mM DTNB / 475 mM EGTA / 0.5 M Tris-HCl pH 8) and 
incubation 5 min, the absorbance at 414 nm was measured against the blank without PLA2. 
Enzymatic activity was measured in µmol of arachidonoyl-thio-PC hydrolyzed/min/ml. 
 
4.4 Phenotype analysis 
 
Phenotype was analyzed by flow cytometry on a FACSCalibur (Becton Dickinson, Franklin 
Lakes, NJ, USA) using FITC-conjugated anti-CD14, -HLA-DR, -CD80 and PE-conjugated 
anti-CD1a, -CD83, -CD86 all from Beckman Coulter. 
 
4.5 Mixed leukocyte reaction (MLR) 
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PBMC were isolated by density gradient centrifugation on Ficoll-Hypaque. After depletion of 
monocytes on Percoll gradient, PBL were recovered in the dense fraction. T lymphocytes 
were purified by immunomagnetic depletion using a cocktail of monoclonal Abs anti-CD19 
(4G7), anti-CD16 (3G8), anti-CD56 (NKH1), anti-glycophorin A (11E4B7.6) and anti-CD14 
(RMO52) all from Beckman Coulter. T lymphocytes were more than 95 % pure as assessed 
by CD3 labeling. Primary MLRs were conducted in 96-well flat-bottom culture plates. DC 
were treated or not at day 5 with PLA2, collected at day 6, extensively washed and 
resuspended in RPMI 1640 supplemented with 2 mM glutamine, 10 mM hepes, 40 ng/ml 
gentamycin and 10 % FCS (BioMedia, Boussens, France). Cells were then co-cultured with 2 
x 105 allogeneic T cells in 200 µl complete culture medium at 1/5, 1/10, 1/20 or 1/40 DC/T 
cells ratio. After 4 days, culture supernatants were tested for the presence of IFNγ by ELISA. 
To detect intracellular IL-4 and IFNγ, 2.104 DC were co-cultured with 2.105 allogeneic T cells 
for 5 days. Cells were restimulated with 100 U/ml recombinant IL-2 (Chiron) for 7 days. Cells 
were washed and incubated with 10 ng/ml PMA and 1 µg/ml ionomycin for 5h. 10 µg/ml 
brefeldin A was added for the last 2h. Cells were washed, fixed and permeabilized with 
cytofix/cytoperm solution (Becton Dickinson) and labeled with anti-IFNγ-FITC and anti-IL-
4-PE (Becton Dickinson). 
 
4.6 Cytokine measurement 
 
Culture supernatants were aliquoted and stored at –80°C. IL-12p40 and IFNγ levels were 
determined using ELISA kits from Biosource (Camarillo, CA, USA) and Endogen (Woburn, 
MA, USA) respectively. IL-12p70 was assayed using the human Th1/Th2 Cytometric Bead 
Array system (BD Biosciences). 
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4.7 PLA2 binding and internalization 
 
Bee venom sPLA2 (2 mg/ml) was labeled with Alexa488-protein labeling kit (Molecular 
Probes, Leiden, The Netherlands). Free Alexa488 was removed by gel filtration and labeled 
protein was recovered in PBS at 1.18 mg/ml.  
The binding of Alexa488-PLA2 was performed on differentiating cells harvested at day 5 and 
resuspended in culture medium. Alexa488-PLA2 was incubated with cells (106/ml) for 20 min 
on ice. In competition experiments, non labeled PLA2 was added into the medium 10 min 
prior to incubation with Alexa488-PLA2 on ice.  
Internalization was carried out at 37°C for 2 to 20 min in RPMI / 10 % LPDS medium. To 
follow receptor-mediated endocytosis, cells were first incubated on ice for 20 min with 10 
µg/ml Alexa488-PLA2, washed twice at 4°C, and then incubated at 37°C for 10 min. 
Internalization was stopped on ice with cold PBS containing 0.1 % BSA and 0.05 % NaN3. 
Cells were washed three times at 4°C in this buffer and analyzed by flow cytometry and 
fluorescence microscopy after cytospin and fixation. Slides were observed with the Leica DM 
IRB/E microscope or the Axioplan2 LSM510 Confocal microscope (Zeiss). 
 
4.8 Electrophoretic Mobility Shift Assay (EMSA) 
 
Differentiating cells were treated with 5 U/ml PLA2 at day 5 for the indicated times (0, 2, 4, 8 
or 24 h) as described above. After treatment, cells (4 x 106) were harvested and nuclear 
proteins were extracted: cells were washed twice with PBS, resuspended in 400 µl of ice-cold 
hypotonic buffer (10 mM Hepes (pH 7.9) / 10 mM KCl / 0.01M DTT / 1.5mM MgCl2 / 1X 
protease inhibitor cocktail (Sigma)), left on ice for 10 min, vortexed and centrifuged at 15,000 
g for 1 min at 4°C. Sedimented nuclei were resuspended in 40 µl ice-cold saline buffer (20 
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mM Hepes (pH 7.9) / 420 mM NaCl / 0.2 mM EDTA / 1.5 mM MgCl2 / 25% glycerol / 1X 
protease inhibitor mixture (Sigma)), left on ice for 20 min, vortexed and centrifuged at 15,000 
g for 5 min at 4°C. Nuclear protein concentrations were determined by Micro-BCA Protein 
Assay Reagent (Pierce, Rockford, IL, USA). The binding activity of nuclear proteins was 
determined using specific DNA probes as described [30]. Sequences of the double-stranded 
oligonucleotide used for detection of NF-κB: 5'-AGTTGAGGGGACTTTCCCAGG-3'; 
PPAR: 5’-GGGGTCAGTAAGTCAGAGGCCAGGGA-3’; AP-1: 5’-
GTGACTCATGACTCATGACTCATGACTC-3’ ; NFAT consensus: 5’-
CGCCCAAAGAGGAAAATTTGTTTCATA-3’. Oligonucleotides were end-labeled with [γ-
32P]ATP (Amersham Biosciences) by T4 polynucleotide kinase (New England Biolab, 
Beverly, MA). For the binding reaction, 1 µg of nuclear extract was added to a reaction 
mixture containing 2 µg of poly (dI-dC) (Amersham Biosciences), 4 µl of 5X binding buffer 
(final concentration: 10 mM Tris (pH 7.5) / 50 mM NaCl / 1 mM DTT / 1 mM EDTA / 5% 
glycerol), and 50000 cpm of [32P]-labeled oligonucleotide in a final volume of 20 µl and were 
incubated at room temperature for 20 min. Unlabeled competitor oligonucleotide was added 
in 50-fold excess to confirm the specificity of the binding reaction. The same amount of total 
protein was loaded on a 4% polyacrylamide non denaturing gel and DNA-protein complexes 
were separated from unbound DNA probe by electrophoresis in 0.5X Tris-glycine EDTA 
buffer. Gels were visualized using a Typhoon PhosphorImager (Molecular Dynamics, 
Sunnyvale, CA). Image Master software (Amersham Biosciences) was used for quantification 
of band intensities that were normalized to non specific background. 
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Figure legends 
 
Fig. 1. Phenotypic maturation induced by bee venom PLA2 
Monocytes were differentiated in LPDS medium containing GM-CSF and IL-4 [22, 23]. Cells 
were treated or not at day 5 with PLA2 or LPS and analyzed at day 6. A, Phenotype of cells 
treated with 5 U/ml PLA2 (filled profile), 5 U/ml PLA2 + polymixin (bold line), 10 ng/ml LPS 
(dotted line) or untreated control cells (thin line). B, Increasing concentrations of PLA2 (0, 2, 
5 or 10 U/ml) were added at day 5 and CD86 expression was analyzed at day 6. Data 
represent mean fluorescent intensities (mfi) normalized at 100 for control non-treated cells. 
Mean ± S.D. of three experiments.  
 
Fig. 2. Functional maturation induced by bee venom PLA2 
Monocytes were differentiated in LPDS medium containing GM-CSF and IL-4. Cells were 
treated or not at day 5 by addition of 5 U/ml PLA2 or 1µg/ml LPS and harvested at day 6. A, 
Control immature DC or PLA2-generated DC were harvested at day 6, washed and cultured 
for 4 days with allogeneic purified T cells (2 x 105/well) at DC / T cell ratios ranging between 
1/5 and 1/40. The amount of IFNγ in the supernatants of the coculture was measured by 
ELISA. B, Control immature DC, PLA2-generated DC or LPS-treated DC were harvested at 
day 6, washed and cultured for 5 days with allogeneic purified T cells (2 x 105/well) at 1/10 
DC/T cell ratio. Cells were expanded with 100 U/ml IL-2 for 7 days, washed and restimulated 
with PMA and ionomycin for 5 hours. Brefeldin A was added for the last 2 hours and cells 
were processed for intracellular labeling with anti-IFNγ-FITC and anti-IL-4-PE. 
 
Fig. 3. Phenotypic and functional maturation induced by the catalytic domain of hGIII-sPLA2 
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Monocytes were differentiated in LPDS medium containing GM-CSF and IL-4. Cells were 
treated or not at day 5 by addition of 700 nM hGIII sPLA2 and analyzed at day 6. A, 
Phenotype of cells treated or not with hGIII sPLA2. Data represent mean fluorescent 
intensities normalized at 100 % for control non-treated cells. B, 104 control immature DC or 
hGIII sPLA2 treated DC were harvested at day 6, washed and cultured for 4 days with 
allogeneic purified T cells (2 x 105/well). The amount of IFNγ in the supernatants of the 
coculture was measured by ELISA. 
 
Fig. 4. Binding and internalization of PLA2 
Monocytes were differentiated in LPDS medium containing GM-CSF and IL-4 for 5 days. 
Cells were washed and resuspended in cold LPDS medium. A, Cells were incubated on ice for 
20 min with increasing doses of Alexa488- PLA2 (0, 4, 8, 16 or 32 µg/ml). After washings, 
the amount of bound fluorescent PLA2 was measured by flow cytometry. Data represent mean 
± S.D. from mean fluorescent intensities (mfi) of three experiments. B, Cells were incubated 
on ice for 20 min with increasing amounts of non labeled PLA2 (20, 50, 100 or 200 µg/ml) 
and 20 µg/ml Alexa488-PLA2. After washing, mean fluorescent intensity of cells was 
measured by flow cytometry. Data are expressed in percentage of PLA2 binding without 
competitor. C, Cells were incubated with 2 µg/ml Alexa488-PLA2 at 37°C or on ice, washed 
and analyzed by flow cytometry. D, Cells were incubated with 4 µg/ml Alexa488-PLA2 on ice 
(up) or at 37°C (bottom), washed and observed in transmission (left) or fluorescence (right) 
microscopy. E, Receptor-mediated endocytosis: cells were incubated with 10 µg/ml 
Alexa488-PLA2 on ice for 20 min, washed and incubated at 37°C for 10 min. Cells were 
washed and analyzed by confocal microscopy. 
 
Fig. 5. Phospholipase activity is essential to induce DC maturation. 
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PLA2 in Hepes-CaCl2 buffer was heated or not at 95°C for 5 to 30 min. A, Enzyme activity 
was assayed by arachidonoyl-thio-PC hydrolysis. B, Monocytes differentiating to DC were 
treated at day 5 with 4 µg/ml of PLA2 heated for the indicated time. Cells were harvested at 
day 6 and their phenotype was analyzed. CD86 expression by PLA2 treated cells was plotted 
against the heating time of PLA2. C, Differentiating cells were washed at day 5, resuspended 
in cold LPDS medium and incubated for 20 min on ice with 4 µg/ml native PLA2 or 4 µg/ml 
denatured PLA2 (95°C for 30 min). Binding was measured as in figure 3. 
 
Fig. 6. EMSA on nuclear extracts from PLA2-generated DC. 
Monocytes differentiating to DC were treated at day 5 with 5 U/ml PLA2 for the indicated 
period of time. Cells were harvested and nuclear extracts prepared as described. Equal 
quantities of nuclear proteins were run for EMSA analysis, using 32P-labeled DNA probes 
specific for NF-κB (A), AP-1, NFAT and PPARγ (B). The specificity of binding was shown 
by competition with non labeled probe in excess (lane C). C, Binding activity of the above 
transcription factors was determined by quantification of band intensities on gel shift assays 
using Image Master software. 
 
 
 
 
 
 27
H
AL author m
anuscript    inserm
-00136390, version 1
HLA-DR CD86CD1a
CD40CD83CD80
Control
PLA2 5 U/ml
PLA2 5 U/ml + 
polymixin
LPS 10 ng/ml
CD14A
B
0
200
400
600
800
1000
0 2 4 6 8 10
PLA2 (U/ml)
C
D
86
 e
xp
re
ss
io
n
 (m
fi)
Figure 1
H
AL author m
anuscript    inserm
-00136390, version 1
0400
800
1200
1600
2000
0 0,05 0,1 0,15 0,2
DC/T cell ratio
IF
N
 g
am
m
a 
se
cr
et
io
n 
(p
g/
m
l)
Control
PLA2
A
B Control PLA2
IFNγ
IL
-4
9 % 19 %
LPS
38 %
9 %
Figure 2
H
AL author m
anuscript    inserm
-00136390, version 1
0200
400
600
800
1000
1200
1400
Control hGIII sPLA2
IF
N γ
 s
ec
re
tio
n 
(p
g/
m
l)
0
50
100
150
200
250
300
350
400
450
HLA-DR CD86 CD80 CD83 CD40
M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 
(%
 o
f c
on
tro
l)
control
hGIII sPLA2
A
B
p < 0.05
Figure 3
H
AL author m
anuscript    inserm
-00136390, version 1
0
20
40
60
80
100
120
140
160
180
200
0 5 10 15 20
time (min)
A
le
xa
-P
LA
2 
(m
fi)
internalization
binding 4°C
A B
4°C 4°C
37°C 37°C
0
20
40
60
80
100
120
0 50 100 150 200
PLA2 (µg/ml)
A
le
xa
-P
LA
2 
bi
nd
in
g 
(%
)
0
5
10
15
20
25
30
35
0 5 10 15 20 25 30 35
Alexa-PLA2 (µg/ml)
B
in
di
ng
 (m
fi)
D
E
C
Figure 4
H
AL author m
anuscript    inserm
-00136390, version 1
050
100
150
200
250
300
0 5 10 15 20 25 30
heating time (min)
C
D
86
 (
m
fi
)
0
20
40
60
80
100
120
0 5 10 15 20 25 30
Heating time (min)
A
ct
iv
it
y 
(%
)
0
2
4
6
8
10
12
14
16
native
enzyme
denatured
enzyme
b
in
d
in
g
 (
m
fi
)
A
C
B
Figure 5
H
AL author m
anuscript    inserm
-00136390, version 1
Time (h)    0     2   4    8   24   C
A
NF-κB Î
B
Time (h)  0    2    4    8   24   C
AP-1 Î
NFAT Î
PPARγÎ
0
50
100
150
200
250
300
0 4 8 12 16 20 24
Time (h)
Bi
nd
in
g 
ac
tiv
ity
 (%
 o
f c
on
tr
ol
)
NF-kB
AP-1
NFAT
PPARg
C
Figure 6
H
AL author m
anuscript    inserm
-00136390, version 1
